An acquisition, a drug license, and a research contract can give a buyer very different things. For life sciences CEOs and business-development teams assessing China biotech export restrictions, the starting question is precise: what technology, rights, and practical capability would cross the border?
Compare the transaction’s substance before relying on its label. Map ownership, know-how, access rights, and deliverables, then have counsel distinguish proposed changes from requirements already in force. Use the matrix below to organize that review—not to infer that a particular deal is permitted.
Does the deal label settle the export-control question?
Treat licensing, ownership transfers, and services as separate diligence questions. Compare the exact rights and technical materials involved, then ask counsel to identify applicable rules, their effective dates, and required permissions. Neither an acquisition headline nor a service contract label is a substitute for that analysis.
Separate the proposal, the operative rule and the procedure
A board paper on China biotech export restrictions should distinguish three questions: what a document proposes, what an operative instrument requires, and what procedure applies to the contemplated transaction. Do not collapse those questions into a single statement that China has banned biotechnology deals.
Start with the official Chinese text. The Ministry of Commerce of the People’s Republic of China, commonly called MOFCOM, is an official-source starting point. Ask counsel to identify the governing instrument, relevant technology entry, publication date, effective date, amendments, and any separate application or registration instructions.
Keep a consultation deadline distinct from an implementation date. Likewise, ask whether a procedural notice changes the substantive treatment of a technology or only explains how a requirement is administered. A document’s publication date alone does not answer those questions.
The deliverable should be a dated conclusion tied to a particular transaction. “Restrictions apply” is not a sufficient instruction to a business-development team. Specify the affected technology, the relevant contractual rights, the action requiring permission, and the point at which that permission must be obtained.
Define the technology before comparing the structures
For this guide, technology transfer means the movement or granting of rights to technical knowledge, methods, or materials. That working description organizes the comparison; counsel must use the definition in the applicable law.
Build the technical inventory before assigning regulatory categories. For cell and gene therapy (CGT), separate the proposed asset from the underlying platform, manufacturing methods, analytical methods, supporting software, and technical assistance. For small interfering RNA (siRNA), use the same discipline: identify exactly which materials, methods, data, and rights the buyer would receive.
Do not treat either scientific label as a legal classification. Ask the technical team to describe the actual capability in plain language and map each deliverable to the relevant legal wording.
A useful question is: Could the buyer independently reproduce or adapt the capability after delivery? Record the answer as a technical observation, not a legal determination. It helps counsel understand whether the transaction concerns access to an output, access to a process, or the ability to operate that process independently.
The Biotech Deal-Structure Impact Matrix
The Biotech Deal-Structure Impact Matrix is Percepture’s editorial comparison tool for this guide. It organizes diligence questions; it does not score legality, predict clearance, or replace technical classification.
Begin with one question: what does the buyer need to own, use, receive, or reproduce? Then compare control, technical delivery, independent use, and the permission question for each route. Keep documentary evidence separate from commercial assumptions. Add the source version and assessment date to the working deal file, and reopen the assessment when either the law or the transaction changes.
| Deal route | Ownership and control | Technical delivery | Independent use | Question for counsel |
|---|---|---|---|---|
| Platform acquisition | Identify the shares, platform assets and intellectual property included. | List methods, materials, know-how, software and training. | Would the buyer operate or develop the platform independently? | Which components and transaction steps require separate analysis or permission? |
| Intellectual-property assignment | Specify the rights changing ownership and any retained rights. | Distinguish legal documents from the technical package delivered. | What capability accompanies the assigned rights? | How does the governing text treat this particular assignment? |
| Therapeutic-asset license | Define territory, field, exclusivity and sublicensing rights. | Separate asset-specific information from reusable platform know-how. | Can the licensee make the asset, or must it rely on the licensor? | How are the granted rights and supporting transfers classified? |
| Contract research | Specify ownership of inputs, study outputs and new inventions. | List reports, datasets, protocols and any technical assistance. | Does the buyer receive results only, or transferable methods too? | Which deliverables or access arrangements require review? |
| Contract development and manufacturing | Allocate process rights, improvements and product-related rights. | Identify batch records, methods, materials and transfer support. | Could another facility reproduce the process using the package? | What analysis applies to manufacturing, technical transfer and a later site change? |
| Joint development | Allocate background rights and rights to future inventions. | Map contributions, shared repositories and technical exchanges. | Can either party independently use the combined work? | Which exchanges and future rights need assessment before collaboration begins? |
| Joint venture | Separate equity ownership, governance and contributed intellectual property. | Document technology contributions and continuing support. | What can the venture and each shareholder access or reuse? | How should each contribution, access right and subsequent transfer be assessed? |
The point is not to rename an acquisition as a license or a service. It is to make the actual package visible. Two agreements with different titles may request similar capabilities; two licenses may grant substantially different rights. Compare the clauses and deliverables, not just the transaction summary.
Is biotech licensing still possible?
For a China biotech licensing decision, frame the question narrowly: can this buyer receive these rights and this technical package under the applicable requirements?
An out-license is a grant of rights by a rights holder to another party. For diligence, distinguish a license to develop or commercialize a specific therapeutic asset from a package that also grants access to reusable platform methods, manufacturing knowledge, or broader technical capabilities.
Have the term sheet identify what is included and excluded. Address the territory, field of use, exclusivity, sublicensing, manufacturing rights, improvements, technical assistance, and rights on termination. Then map the technical delivery to those provisions.
Avoid the blanket conclusion that licensing is either universally available or universally prohibited. Ask counsel for an agreement-specific answer. If the buyer’s commercial objective requires rights outside the assessed package, return to the analysis rather than treating the original conclusion as portable.
Ownership acquisition and services need different questions
In an acquisition, ask what changes hands through ownership and control. In a services engagement, ask what work will be performed, where it will be performed, what access is provided, and what the customer receives.
A contract research organization (CRO) performs research services. A contract development and manufacturing organization (CDMO) performs development and manufacturing services. These descriptions identify business models, not regulatory outcomes.
For a service agreement, request an explicit deliverables schedule. Does the customer receive a finished report, raw data, a reproducible protocol, a manufacturing package, source code where relevant, or training? Who receives access to the supplier’s systems, and from where? Will the engagement later expand into technical transfer?
Review the exit plan at the same time. A buyer seeking supplier portability should identify the information, materials, rights, and assistance needed to move the work. Put that proposed transfer into the diligence scope rather than leaving it as an assumption for a later procurement phase.
U.S. biotech evaluating a Chinese technology-platform purchase versus licensing
Illustrative case scenario (hypothetical)
Not a real client or completed transaction. An American biopharma company is considering three routes to support a development program: acquiring proprietary CGT platform intellectual property, licensing one therapeutic asset, or commissioning a CRO study. No approval, cost saving, or business outcome is assumed.
Route one: purchase the platform intellectual property
Suppose the proposed package includes ownership of specified rights, operating methods, supporting software, and training. The buyer’s technical team should explain what it could reproduce after receiving that package. Counsel should map the components to the precise technology categories and applicable requirements, including any relevant proposal separately from operative law.
The contractual questions include ownership, retained seller rights, third-party dependencies, access to know-how, and the consequences if a component cannot be delivered. Source code belongs in the inventory only if it is actually part of this hypothetical package—not because every biotech platform necessarily includes it.
Route two: license a single therapeutic asset
Suppose the alternative grants development and commercialization rights for one asset while excluding general platform methods. Compare that stated boundary with the technical-assistance and manufacturing provisions. Does the buyer also require process knowledge or broader rights to meet its commercial objective?
Counsel must assess the exact licensed rights, supporting know-how, relevant technology categories, and regulatory permissions. The narrower description is an assumption to test against the contract, not a conclusion that the route is permitted.
Route three: commission a CRO study
Suppose the supplier conducts a defined study and delivers a report and dataset, with no platform ownership transfer. Identify whether the agreement also provides protocols, source code, training, or rights to new methods. Review confidentiality, data access, ownership of new inventions, and any subsequent technical handover.
The three routes should produce three separate rights-and-deliverables maps. Counsel must evaluate the precise draft terms and applicable law for each. The buyer should compare only routes that satisfy its actual technical objective; a research output is not automatically a substitute for an independently usable platform.
What deal counsel should verify
Ask counsel to return a short written assessment of China biotech export restrictions tied to the contemplated agreement and its technical annexes. Make it usable by the CEO, business-development lead, technical owner, and procurement team.
Build one transaction-specific review file
- Governing text: Identify the authoritative instrument, relevant entry, version and effective date.
- Legal status: Distinguish proposals, operative requirements and procedural instructions.
- Technical scope: Match the actual methods, materials, software, know-how and assistance to the legal analysis.
- Transaction scope: Include ownership, licensing, access, subcontracting, sublicensing and later transfers.
- Permissions and sequence: Identify any applicable application, registration, approval or other requirement and its place in the deal timeline.
- Contract consequences: Address conditions, payment triggers, delivery limits, termination and change management.
- Reassessment triggers: Record which legal changes or changes to rights and deliverables would require a fresh review.
Compare diligence costs without inventing a price
Request a scoped budget for technical classification, legal analysis, translation, counterparty diligence, and any applicable permission process. Separate one-time work from recurring monitoring or support. Use actual adviser estimates and contractual payment terms rather than an industry-wide price assumption.
For the finance team, build timing cases from stated assumptions: the planned sequence, a delay requiring additional work, and a route that cannot proceed as intended. Show which payments, internal resources, and development dependencies are exposed in each case. Do not turn an assumed delay or approval probability into a reported fact.
Keep the deal brief and the public message separate
Use two documents: a detailed legal and technical file, and a shorter commercial explanation derived from it. The public explanation should preserve the distinction between proposed and effective requirements without exposing confidential terms.
For a manufacturer, that discipline also belongs in service descriptions and partner conversations; Percepture’s CDMO marketing guide addresses the separate marketing workstream. When preparing a transaction announcement, scope the communications assignment separately from counsel’s analysis; public relations programs are a communications service, not a substitute for a legal conclusion.
Resolve the open questions before choosing a route
Before committing, ask what would change the assessment: a different platform component, broader manufacturing rights, a new subcontractor, remote technical access, additional training, or a later transfer to another facility. Record the decision owner for each unresolved item and the commercial consequence of leaving it open.
The useful output of a China biotech export restrictions review is not a red, amber, or green label attached to a headline. It is a dated explanation of the specific rights and capabilities the buyer can pursue, the conditions counsel identifies, and the assumptions that must remain true.
Bring the matrix, proposed agreement, and technical inventory into the same discussion. That gives the CEO a decision, counsel a defined scope, and the operating team a package it can evaluate before signing.
About Bob Generale
Bob Generale is President of Percepture.
Meet the Percepture team or connect with Bob Generale on LinkedIn.
